Recovery From Acute Immune Failure in Septic Shock by Immune Cell Extracorporeal Therapy - Observational Long-term Outcome Follow up

ConditionSevere Sepsis
Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18-80
SponsorArtcline GmbH

About this trial

Subjects previously enrolled / randomized in the ReActIF-ICE (Recovery from acute immune failure in septic shock by immune cell extracorporeal terapy - immune competence enhancement) study received either standard sepsis treatment (control group) or standard sepsis treatment and additionally the ARTICE treatment (treatment group) during their index hospitalization. All subjects are followed up for 90 days after enrollment.

In this long term follow up study, the enrolled subjects shall be followed up beyond 90 days for up to 5 years.

Eligibility criteria

Qualifiers

Subject or legal surrogate is willing and able to provide written informed consent and comply with all protocol requirements or the implementation of other established procedures according to the local regulations of the contributing center to include subjects who are unable to provide informed consent.

Subject was enrolled in the ReActIF-ICE study and successfully passed the Day 2 re-evaluation of that trial.

Disqualifiers

none

Trial design

Treatments tested in this trial

  • Not listed

Trial groups

142 Participants
are grouped into 2 trial groups

Sponsors and collaborators

Artcline GmbH

Lead sponsor

ZKS Jena

Collaborator